Obeticholic acid yields fewer deaths, liver transplants in primary biliary cholangitis

Patients who received obeticholic acid for primary biliary cholangitis experienced greater transplant-free survival compared with external control patients, according to research published in Gastroenterology.
“This important study is the first to demonstrate that initiating treatment with obeticholic acid (OCA) in appropriate patients with primary biliary cholangitis (PBC) appears to have a meaningful impact on clinical outcomes,” Gideon Hirschfield, FRCP, PhD, Lily and Terry Horner Chair in autoimmune liver disease at the University of Toronto, said in a press release.
Although

Patients who received obeticholic acid for primary biliary cholangitis experienced greater transplant-free survival compared with external control patients, according to research published in Gastroenterology.
“This important study is the first to demonstrate that initiating treatment with obeticholic acid (OCA) in appropriate patients with primary biliary cholangitis (PBC) appears to have a meaningful impact on clinical outcomes,” Gideon Hirschfield, FRCP, PhD, Lily and Terry Horner Chair in autoimmune liver disease at the University of Toronto, said in a press release.
Although